<DOC>
	<DOCNO>NCT01358253</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy Rituximab combine chemotherapy CD20+ adult acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Rituximab Plus Chemotherapy CD20+ Adult Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Acute lymphoblastic leukemia ( ALL ) group biologically heterogeneous disease diverse prognosis . Novel strategy adult ALL approach CR rate 80 % , similar pediatric ALL . But long term survival adult ALL 30 % -40 % , much low pediatric patient . In trial , patient first receive Vincristine 1.4mg/m2 , max 2mg IV day 1,8,15,22 , Daunorubicin 45mg/m2 IV day 1-3 , Cyclophosphamide 750mg/m2 IV day 1 prednisone 40-60mg/m2 , mouth day 1-14 ( VDCP ) regimen initial induction therapy . If patient achieve complete remission induction , enrol study consolidation maintenance . If tumor cell bone marrow remain 5 % 20 % induction , patient receive VDCLP ( VDCP+L-asparaginase 6000IU/m2 IV days5,7,9,11,13 ) enrol complete remission . Rituximab main experimental intervention study.The consolidation regimen HyperCVAD/MA R-HyperCVAD/MA totally 8 course . The maintenance regimen include 6-Mercaptopurine+Methotrexate 24 month , Vincristine+Prednisone first 12 month , L-asparaginase month 3 9 without Rituximab month 6 12 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnosis CD20positive ALL Adequate liver function ( bilirubin less equal 1.5*ULN , unless consider due tumor ) , renal function ( creatinine less equal 1.5*ULN , unless consider due tumor ) Signed informed consent Prior history treatment highdose AraC , MTX rituximab Pregnant lactate woman History allergy rituximab Unable sign inform consent Active replication HBV History stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>HyperCVAD</keyword>
</DOC>